POS-336 SEMAGLUTIDE 2.4 MG AND 1.0 MG IMPROVED ALBUMINURIA IN ADULTS WITH OVERWEIGHT/OBESITY AND TYPE 2 DIABETES IN STEP 2
Hiddo J.L. Heerspink(University Medical Center Groningen), David Z.I. Cherney(University Health Network), Ellen M. Apperloo(Dialyse Centrum Groningen), Julio Rosenstock(Velocity Clinical Research (United States)), Kristian Kandler(Novo Nordisk (Denmark)), Melanie J. Davies(NIHR Leicester Biomedical Research Centre), Dror Dicker(Tel Aviv University), Niels Zeuthen(Novo Nordisk (Denmark)), Rasmus Sørrig(Novo Nordisk (Denmark))
Cited by 2
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2018|3.5k